- Home
- RLTY vs GOSS Comparison
RLTY vs GOSS Comparison
Compare RLTY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- GOSS
- Stock Information
- Founded
- RLTY 2022
- GOSS 2015
- Country
- RLTY United States
- GOSS United States
- Employees
- RLTY N/A
- GOSS N/A
- Industry
- RLTY Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- GOSS Health Care
- Exchange
- RLTY Nasdaq
- GOSS Nasdaq
- Market Cap
- RLTY 256.4M
- GOSS 246.6M
- IPO Year
- RLTY N/A
- GOSS 2019
- Fundamental
- Price
- RLTY $16.32
- GOSS $1.07
- Analyst Decision
- RLTY
- GOSS Strong Buy
- Analyst Count
- RLTY 0
- GOSS 5
- Target Price
- RLTY N/A
- GOSS $9.20
- AVG Volume (30 Days)
- RLTY 86.7K
- GOSS 969.4K
- Earning Date
- RLTY 01-01-0001
- GOSS 11-07-2024
- Dividend Yield
- RLTY 9.35%
- GOSS N/A
- EPS Growth
- RLTY N/A
- GOSS N/A
- EPS
- RLTY N/A
- GOSS N/A
- Revenue
- RLTY N/A
- GOSS $95,842,000.00
- Revenue This Year
- RLTY N/A
- GOSS N/A
- Revenue Next Year
- RLTY N/A
- GOSS N/A
- P/E Ratio
- RLTY N/A
- GOSS N/A
- Revenue Growth
- RLTY N/A
- GOSS N/A
- 52 Week Low
- RLTY $11.38
- GOSS $0.45
- 52 Week High
- RLTY $14.60
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- RLTY 41.86
- GOSS 62.64
- Support Level
- RLTY $16.72
- GOSS $0.98
- Resistance Level
- RLTY $17.28
- GOSS $1.07
- Average True Range (ATR)
- RLTY 0.35
- GOSS 0.07
- MACD
- RLTY -0.15
- GOSS 0.01
- Stochastic Oscillator
- RLTY 5.87
- GOSS 83.26
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.